However, there is a piece of exciting news that the US FDA has approved Merck’s innovative oncology drug Welireg, the first HIF2α inhibitor, for the treatment of VHL syndrome-related tumors. This evidence concerns the gene EPAS1 and von Hippel-Lindau disease.